PBM
Psyence Biomedical Ltd. Common SharesKey Statistics
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. (PBM) is a pioneering biotechnology company dedicated to unlocking the therapeutic potential of psychedelic compounds, specifically in the realms of mental health and wellness. By employing a vertically integrated approach, Psyence excels in the cultivation, formulation, and clinical research of psilocybin and other psychedelic substances, with the objective of developing innovative therapies to address pressing mental health issues. Supported by a strong intellectual property portfolio and a promising clinical pipeline, the company is well-positioned to capitalize on the growing acceptance of psychedelics in healthcare, addressing the urgent demand for accessible and effective mental health solutions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-4.15M |
| Operating Margin | 0.00% |
| Return on Equity | -74.30% |
| Return on Assets | -34.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $39.62 |
| Price-to-Book | 0.97 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 6.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.29M |
| Float | 292,590 |
| % Insiders | 4.45% |
| % Institutions | 1.43% |
Historical Volatility
Volatility is currently expanding